 SAN FRANCISCO and SAN DIEGO, Dec. 02, 2020 GLOBE NEWSWIRE -- Kinnate Biopharma Inc. Nasdaq: KNTE Kinnate, a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of 20.00 per share. All of the shares of common stock are being offered by Kinnate. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kinnate, are expected to be 240.0 million, excluding any exercise of the underwriters option to purchase additional shares. Kinnates common stock is expected to begin trading on the Nasdaq Global Select Market on December 3, 2020 under the symbol KNTE. The offering is expected to close on December 7, 2020, subject to the satisfaction of customary closing conditions. In addition, Kinnate has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. 